Oliver Nayler

This inventor holds 38 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 20 EPO patents, primarily in S1P Receptor Agonists. Top assignees: Actelion Pharmaceuticals Ltd, Other. Active years: 2004-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Oliver Nayler. Retrieved from https://idiyas.com/inventor/oliver-nayler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 5)

% Patents Active = 47.4

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 20 (Patent Applications = 13)

Average Co-Inventor Count = 6.4

ph-index = 11

Forward Citations = 366(Granted Patents)

Location History:

Allschwil, CH (2014 - 2019)
Arlesheim, CH (2004 - 2020)

Company Filing History:

37 out of 217

Actelion Pharmaceuticals Ltd

patents

1 out of 834,570

Other

patents

Years Active: 2004-2020

Loading Chart...

Areas of Expertise:

S1P Agonists

Pyridine Derivatives

Thiazolidin Derivatives

Immunomodulators

Tryptophan Hydroxylase Inhibitors

Pyrimidine Derivatives

Tricyclic Compounds

Phenyl Derivatives

Thiophene Derivatives

Quinoline Derivatives

Amino-Pyridine Derivatives

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10660880 - Dosing regimen for a selective S1Pagonist (2020-05-26),

2. 10251867 - [object Object] (2019-04-09),

3. 10189839 - Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase (2019-01-29),

4. 9765092 - Tricyclic piperidine compounds (2017-09-19),

5. 9617250 - Pyridin-4-yl derivatives (2017-04-11),

6. 9133179 - 2-methoxy-pyridin-4-yl-derivatives (2015-09-15),

7. 9000018 - Thiazolidin-4-one-derivatives (2015-04-07),

8. RE45174 - Thiazolidin-4-one derivatives (2014-09-29),

9. 8785484 - Dosing regimen for a selective S1P1 receptor agonist (2014-07-22),

10. 8697732 - Pyridine derivatives (2014-04-15),

11. 8658675 - Pyridin-4-yl derivatives (2014-02-25),

12. 8598208 - Pyridine derivatives as S1P1/EDG1 receptor modulators (2013-12-03),

13. 8592460 - Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists (2013-11-26),

14. 8580824 - Pyridin-4-yl derivatives as immunomodulating agents (2013-11-12),

15. 8575200 - Pyridin-2-yl derivatives as immunomodulating agents (2013-11-05),

Certainly! Here is the article about inventor Oliver Nayler:

Title: Oliver Nayler: Pioneering Inventor in Healthcare Technology

Introduction:

Oliver Nayler, a visionary inventor based in Arlesheim, Switzerland, is renowned for his passion for innovation and his unwavering commitment to leveraging technology for a better future. With a staggering 38 patents to his name, Nayler is a trailblazer in the field of healthcare technology, continually pushing boundaries to create solutions that enhance lives.

Latest Patents:

Among his latest patents is a groundbreaking dosing regimen for a selective S1P receptor agonist. This innovation revolutionizes the administration of the selective S1P receptor agonist to induce desensitization of the heart effectively. Nayler's meticulous approach to dosing frequency and titration showcases his dedication to precision and efficacy in medical treatment.

Career Highlights:

Oliver Nayler's illustrious career has seen him make significant contributions to the field of healthcare technology. Notably, he has worked with reputable companies such as Actelion Pharmaceuticals Ltd, where his innovative mindset and inventive spirit have driven breakthroughs in pharmaceutical research and development. Nayler's keen focus on improving patient outcomes sets him apart as a visionary in the industry.

Collaborations:

Throughout his career, Oliver Nayler has collaborated with esteemed professionals in the field, including coworkers Boris Mathys and Claus Mueller. These collaborations have enriched Nayler's innovative projects, bringing together diverse expertise and perspectives to drive progress in healthcare technology. His ability to work synergistically with peers highlights his collaborative spirit and commitment to collective advancement.

Conclusion:

Inventor Oliver Nayler's remarkable journey epitomizes a relentless pursuit of innovation and a fervent dedication to creating positive change through technological advancements in healthcare. His pioneering work in dosing regimens and pharmaceutical research underscores his impact on the industry, inspiring generations of inventors to push boundaries and redefine what is possible in healthcare technology. Oliver Nayler's legacy will undoubtedly endure as a beacon of ingenuity and excellence in the realm of inventions and patents.

Profile summary based on public USPTO records.